Cellectis

Cellectis CapEx/D&A

CapEx to Depreciation Ratio of Cellectis (CLLS) as of Oct 18, 2026.

CapEx/D&A

-

Last updated:

CapEx to Depreciation Ratio of Cellectis is 2026 - . CapEx to Depreciation Ratio of Cellectis was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cellectis Stock analysis

What does Cellectis do? Cellectis SA, headquartered in Paris, France, is a clinical-stage biotechnology company specializing in gene-editing technologies. It develops allogeneic CAR-T cell therapies for immuno-oncology, including product candidates like BALLI-01 for relapsed/refractory acute lymphoblastic leukemia and NatHaLi-01 for B-cell non-Hodgkin's lymphoma. The company also focuses on gene therapy for other therapeutic areas, with additional candidates targeting large B-cell lymphoma and renal cell carcinoma. Founded in 1999, it has 222 employees and has been listed on the stock market since 2007. Cellectis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cellectis stock

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio Cellectis since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's Cellectis with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cellectis

All Key Metrics — Cellectis